MarketPulse

X-linked retinitis pigmentosa

2 articles
BenzingaBenzinga··Vandana Singh

MeiraGTx Reacquires Eye Disease Drug From J&J for $25M, Eyes 2027 Launch

MeiraGTx reacquires J&J's eye disease drug bota-vec for $25M, raises $100M in funding, targeting 2027 launch. Stock falls 15.8%.
JNJLLYMGTXcapital raiseregulatory approval
BenzingaBenzinga··Globe Newswire

MeiraGTx Acquires Johnson & Johnson's Gene Therapy for Rare Blindness

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.
JNJMGTXFDA approvalclinical trial